None reported

Fever, chills, fatigue, infection, pain, weakness, parethesia, headache, visual disturbance, cough, pneumonia, dyspnea, sinusitis, nausea, vomiting, anorexia, stomatitis, GI bleeding

Hypersens to the drug Special precaution: Monitoring the patients hematologic profile. Hetatologic toxicity- closely observe patients of hematologic and nonhematologic toxicity.

Fludarabine was approved by FDA in April 1991

Chronic lymphocytic leukemia.

Dosage:

Usual dose 25mg/m2 administered over a period of about 30 minutes daily for 5 consecutive days.

Pharmacology:

Fluadarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine that is relatively resistent to deamination by adenosine deaminase.

Pharmacokinetics:

Fludarabine is rapidly converted to the active 2-fluoroara-A, within minutes after IV infusion. Total body clearance is inversely correlated with serum creatinine,suggesting renal elimination of the compound.

Pregnancy:

Avoid women of child bearing potential to avoid becoming pregnant.

Lactation:

Excercise caution and decide whether to discontinue the drug or discontinue nursing, depending on the importance of the drug to the mother.